Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zirconium Zr-89 DFO-pertuzumab
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zirconium Zr-89 DFO-pertuzumab is a radiopharmaceutical imaging agent consisting of the monoclonal antibody pertuzumab conjugated with desferrioxamine (DFO) chelator and labeled with the positron-emitting radioisotope zirconium-89. It functions as an immuno-PET tracer designed to bind specifically to the human epidermal growth factor receptor 2 (HER2), enabling noninvasive visualization and quantification of HER2 expression in tumors. The radiopharmaceutical has a half-life of approximately 78.4 hours, making it suitable for antibody-based imaging applications where optimal tumor-to-background ratios are achieved several days after injection.
- Other names
- zirconium Zr 89 DFO-pertuzumabZr 89-DFO-pertuzumabZr89-DFO-pertuzumabZr-89-DFO-pertuzumab
02
Targets
HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)
Beyond the preview
Go deeper on zirconium Zr-89 DFO-pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zirconium Zr-89 DFO-pertuzumab.